Optinose Inc is planning an initial public offering of shares of its common stock to raise $100m.

Based in the US, Optinose is a nasal delivery technology developer. The company plans to use the proceeds from the offering to advance the development of its XHANCE product and for general corporate purposes.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Cofactor Genomics Inc has secured $18m in a series A funding round led by Menlo Ventures and joined by existing investor Data Collective Venture Capital LLC.

The US-based biotech company involved in developing RNA-based diagnostic kits plans to use the funds to enhance its research and development.

"The UK-based robotic systems developer secured $20.3m in July in a series A funding round led by ABB Technology Ventures, bringing the total funds to $46m."

MediWound Ltd plans for an underwritten public offering of shares. The offering also includes a 30-day option for underwriters to purchase 15% of ordinary shares.

See Also:

The Israeli biotech company plans to use the funds towards research and development, as well as general corporate purposes.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Cambridge Medical Robotics Ltd (CMR) has secured an additional $26m in a series A funding round headed by Watrium and ABB Technology Ventures.

The UK-based robotic systems developer secured $20.3m in July in a series A funding round led by ABB Technology Ventures, bringing the total funds to $46m. The company plans to use the stocks to advance the development of its Versius surgical robotic system.